UK markets closed

Kiromic BioPharma, Inc. (KRBP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.8601+0.2301 (+6.34%)
At close: 03:57PM EDT
3.8900 +0.03 (+0.77%)
After hours: 07:33PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.81M
Enterprise value 4.55M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.54
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.12

Trading information

Stock price history

Beta (5Y monthly) 0.22
52-week change 3-84.99%
S&P500 52-week change 3-10.33%
52-week high 327.0000
52-week low 33.1600
50-day moving average 35.1255
200-day moving average 38.6084

Share statistics

Avg vol (3-month) 3102.05k
Avg vol (10-day) 364.26k
Shares outstanding 5683.49k
Implied shares outstanding 6N/A
Float 8484.6k
% held by insiders 14.13%
% held by institutions 110.94%
Shares short (14 Mar 2023) 433.7k
Short ratio (14 Mar 2023) 40.25
Short % of float (14 Mar 2023) 45.22%
Short % of shares outstanding (14 Mar 2023) 44.93%
Shares short (prior month 14 Feb 2023) 44.23k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 312 Mar 2023

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-82.80%
Return on equity (ttm)-202.66%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -33.17M
Net income avi to common (ttm)-38.64M
Diluted EPS (ttm)-76.0900
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)432.7k
Total cash per share (mrq)0.71
Total debt (mrq)2.17M
Total debt/equity (mrq)765.26
Current ratio (mrq)0.19
Book value per share (mrq)0.54

Cash flow statement

Operating cash flow (ttm)-28.81M
Levered free cash flow (ttm)-16.95M